2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Cell Expansion, Treatment Considerations, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Pharmacology, Biological Processes, Immune Mechanism, Diseases, Bleeding and Clotting, Platelet Disorders, Immunology, Autoimmune Disorders, Autoimmune Hemolytic Anemia, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Non-Hodgkin Lymphoma, T Cell Lymphoma, Research, Fundamental Science, AML, Translational Research, Study Population, Human, Animal Model
PAPER

2381 Quail-100 induces distinct, multifunctional γδ T cell responses with enhanced durability compared to zoledronic acid in post-HSCT pediatric leukemia patients

Wenjun Wang, MD, PhD, Anay Limaye2, Giulia Barbarito, MS3, Orly Klein, MD4, Barbara Troupin5, Isobel Hawes, PhD6, Chris Rae, PhD7, Robertson Parkman, MD8, Jonathan Kotula, PhD9, Alice Bertaina, MD, PhD10
1 Stanford University School of Medicine, Stanford, California, United States
2 Stanford University School of Medicine, Stanford, California, United States
3 Stanford University School of Medicine, Stanford, California, United States
4 Stanford University School of Medicine, Stanford, California, United States
5 Laguna Biotherapeutics, San Francisco, California, United States
6 Stanford University School of Medicine, Stanford, California, United States
7 Laguna Biotherapeutics, San Francisco, California, United States
8 Stanford University School of Medicine, Stanford, California, United States
9 Laguna Biotherapeutics, San Francisco, California, United States
10 Stanford University School of Medicine, Stanford, California, United States

Background: γδ T cells mediate potent anti-leukemic and anti-infective immunity following allogeneic hematopoietic stem cell transplantation (HSCT); however, standard Vγ9Vδ2 activation with zoledronic acid (ZOL) induces rapid terminal differentiation and functional exhaustion, limiting sustained therapeutic efficacy. Pathogen-driven γδ T cell responses, including those elicited by cytomegalovirus (CMV), exhibit greater functional diversity and durability, providing a conceptual framework for multimodal activation strategies. QUAIL-100, a quadruple-attenuated Listeria monocytogenes strain (Lm ΔactA/ΔinlB/ΔribC/ΔribF), was evaluated as a novel γδ T cell activator that engages combinatorial signals including phosphoantigens, pathogen-associated molecular patterns, and co-stimulatory pathways.

Methods: Peripheral blood mononuclear cells (PBMCs) from healthy donors (N=7) and pediatric patients at day 30 following αβ-depleted haploidentical HSCT (N=8) were stimulated with QUAIL-100 (MOI 20 + rhIL-2), ZOL (5 µM + rhIL-2), CMV peptide pool (0.01 µg/mL + rhIL-2), or rhIL-2 alone. γδ T cell activation, exhaustion, cytotoxicity, subset composition, and migratory capacity were profiled longitudinally over 10 days by multiparameter flow cytometry. Functional capacity was assessed via CD107a degranulation and Calcein-AM cytotoxicity assays against multiple AML cell lines. Single-cell RNA sequencing (scRNA-seq) with integrated AbSeq surface protein profiling and V(D)J sequencing characterized transcriptional, proteomic, and clonotypic signatures at day 7.

Results: QUAIL-100 induced progressive γδ T cell expansion with balanced Vδ1/Vδ2 representation, in contrast to the transient, preferential Vδ2-dominant expansion followed by contraction observed under ZOL. Exhaustion markers (TIM-3, CTLA-4) were significantly reduced under QUAIL-100 stimulation, whereas expression of migration-associated markers (CCR1, ITGA1, SELL) was significantly elevated. QUAIL-100-activated γδ T cells achieved significantly greater cytotoxicity against a broad panel of AML targets (THP1, K562, MOLM13, MV4-11, and Kasumi-6), reducing live AML cell frequency compared with both IL-2 and ZOL-activated controls across multiple effector-to-target ratios (P<0.05 to P<0.0001). This cytotoxic advantage extended to primary AML blasts, supporting translational relevance. Consistent with enhanced target engagement, QUAIL-100-activated γδ T cells also showed greater CD107a degranulation across all five target lines tested, with surface mobilization increasing progressively at higher effector-to-target ratios relative to unstimulated conditions. QUAIL-100 sustained granzyme A and B expression through day 10, uniquely induced granzyme K (GZMK) from day 6 onward, and generated a larger polyfunctional GZMA⁺GZMB⁺IFN-γ⁺ population with greater durability than ZOL. scRNA-seq identified 13 transcriptionally distinct clusters across conditions. QUAIL-100 generated 3 unique clusters absent from ZOL populations: Th1-like CTL (IFN-γ⁺CD39⁺, 35% of QUAIL-100 cells), tissue-resident memory CTL (ITGA1⁺, 28%), and cycling CTL (TOP2A⁺CENPF⁺, 22%), whereas ZOL generated a single homogeneous Th2-biased effector cluster (IL-4⁺IL-5+IL-13⁺) comprising 88.7% of ZOL-activated cells. Pathway enrichment highlighted IFN-γ response, allograft rejection, and NK cell-mediated cytotoxicity in QUAIL-100-enriched clusters. TCR repertoire analysis demonstrated significantly greater clonotypic diversity in QUAIL-100-activated cells by Shannon entropy and Gini-Simpson indices. Validation in post-HSCT patient samples confirmed that QUAIL-100 maintained balanced Vδ1/Vδ2/double-negative subset diversity, robust cytotoxic programming, and minimal exhaustion marker expression.

Conclusions: QUAIL-100 generates functionally diverse, transcriptionally heterogeneous, and durably cytotoxic γδ T cell responses superior to ZOL across kinetic, phenotypic, functional, and transcriptomic dimensions. These preclinical findings directly informed an FDA-authorized first-in-human clinical trial of QUAIL-100 (NCT07573111), with patient enrollment commencing imminently, supporting the clinical development of QUAIL-100 as a novel immunotherapeutic strategy to enhance durable anti-leukemic and anti-infective immunity in pediatric HSCT recipients.

KEYWORDS: γδ T cells, QUAIL-100, zoledronic acid, HSCT, pediatric leukemia, HMBPP, graft-versus-leukemia, immunotherapy

Wenjun Wang, MD, PhD: No relevant conflicts of interest to declare.